Adam B. Weiner, Urologic Oncologist at Cedars Sinai Medical Center, shared on X:
“CAPItello-281 OS update: capivasertib + abiraterone extended survival by ~11 mo in PTEN-deficient de novo mHSPC prostate cancer.
- n=1012, PTEN-deficient de novo metastatic hormone-sensitive PCa
- Phase 3 RCT, updated OS (descriptive, 42% maturity)
- Capivasertib + abiraterone + ADT vs placebo + abiraterone + ADT
- +17 mo f/u, data cutoff Mar 2026
–
- Median OS 57.4 vs 46.5 mo, HR 0.82 (95% CI 0.68-0.99), p=0.044
- Deaths 38.5% vs 44.8%; median OS reached in both arms for the first time
- Deeper signal with deeper PTEN loss
Descriptive analysis at 42% maturity with CI upper bound at 0.99. 0
Adding the AKT inhibitor to abiraterone improved OS in PTEN-deficient subset.”
Title: Capivasertib plus abiraterone in PTEN-deficient de novo metastatic hormone-sensitive prostate cancer: updated survival analysis from CAPItello-281
Authors: K. Fizazi, N.W. Clarke, M. De Santis, H. Uemura, A.P. Fay, N. Karadurmus, C. Alvarez-Fernandez, S. Jiang, D. Parslow, M. Sotelo, Y. Ürün, N. Oliveira, T. Gyun Kwon, M. Özgüroğlu, G. Roubaud, D. Castellano, J.K. Logan, T. Morris, C. Gresty, D.J. George
You can also read:
